PriceSensitive

ZEN Graphene (TSXV:ZEN) files patent for virucidal ink component

Sponsored
28 September 2020 16:01 (EDT)

ZEN Graphene Solutions (ZEN) and Guelph University have filed a provisional patent for a method related to its virucidal ink.

The patent is for an electrochemical exfoliation (ECE) process which produces graphene oxide (GO) from Albany Pure graphite. This graphene oxide is a key ingredient in the production of ZEN Graphene’s newly developed, graphene-based antiviral ink.

The company intends to optimise and scale-up this ECE process for producing graphene oxide, as it works to produce its ink on a larger scale.

Last week, ZEN Graphene announced that testing of its ink had produced promising results of significant virucidal activity. The ink was 99 per cent effective against the COVID-19 virus, even 35 days after the ink was applied to mask material.

The announcement of this news caused ZEN Graphene’s share price to spike as high as 72 per cent on that day. With many companies keen to apply the antiviral ink to their products, the company is working to protect its technologies and methodologies.

ZEN Graphene’s CEO, Dr Francis Dube, commented on the company’s ongoing process to patent, protect, and commercialise its ink product.

“This second provisional patent application in a week creates a solid commercial foundation for the company to launch its first commercial product, our virucidal ink, at a crucial time when COVID-19 is starting its second wave.

“We believe ZEN’s product can make a serious contribution in the fight against this global pandemic,” he said.

ZEN Graphene Solutions (ZEN) is up 8.06 per cent and is trading at 67 cents per share, as of 2:53pm EDT.

Related News